&lt;p&gt;Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis&lt;/p&gt;

Liu, Liwen; Bu, Xiaomin; Wu, Bin; Zhang, Shuyuan; Jin, Kai; Liang, Xiaofeng; Sun, Chao

doi:10.2147/cmar.s268990

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In neonates suffering from hypoxic-ischemic encephalopathy (HIE), levels of B2M in cerebrospinal fluid are significantly increased and correlates with the severity of HIE, which suggests a promising avenue for utilizing B2M as a marker to monitor the extent of inflammation and response to treatment in HIE cases (Carreras et al 2023 ). Serum B2M might also serve as one of indicators for distinguishing high-grade gliomas and brain metastases (Li et al 2020 ). An increasing number of studies have focused on the roles of B2M in CNS diseases.…”

Section: Introductionmentioning

confidence: 99%

The Role of Beta2-Microglobulin in Central Nervous System Disease

Liu,

Tang,

Yang

et al. 2024

Cell Mol Neurobiol

View full text Add to dashboard Cite

Central nervous system (CNS) disorders represent the leading cause of disability and the second leading cause of death worldwide, and impose a substantial economic burden on society. In recent years, emerging evidence has found that beta2 -microglobulin (B2M), a subunit of major histocompatibility complex class I (MHC-I) molecules, plays a crucial role in the development and progression in certain CNS diseases. On the one hand, intracellular B2M was abnormally upregulated in brain tumors and regulated tumor microenvironments and progression. On the other hand, soluble B2M was also elevated and involved in pathological stages in CNS diseases. Targeted B2M therapy has shown promising outcomes in specific CNS diseases. In this review, we provide a comprehensive summary and discussion of recent advances in understanding the pathological processes involving B2M in CNS diseases (e.g., Alzheimer's disease, aging, stroke, HIV-related dementia, glioma, and primary central nervous system lymphoma).

show abstract

Section: Introductionmentioning

confidence: 99%